33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Exploring alternative dosing regimens of single-agent belantamab mafodotin on safety and efficacy in patients with relapsed or refractory multiple myeloma: DREAMM-14
    Meeting Abstract

    Hultcrantz, M.; Kleinman, D.; Ghataorhe, P.; McKeown, A.; He, W.; Ling, T.; Jewell, R. C.; Brunner, J.; Byrne, J.; Eliason, L.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Belantamab mafodotin in patients with relapsed/refractory multiple myeloma, a real-world experience
    Meeting Abstract

    Hultcrantz, M.; Orozco, J.; Peterson, T. J.; Derkach, A.; Hassoun, H.; Korde, N.; Lu, S. X.; Mailankody, S.; Patel, D.; Shah, U. A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Lesion characteristics and patterns of failure in diffuse large B cell lymphoma patients treated with bridging radiotherapy prior to chimeric antigen receptor T cell therapy
    Meeting Abstract

    Hubbeling, H.; Silverman, E. A.; Wijetunga, N. A.; Palomba, M. L.; Tringale, K.; Lebow, E.; Tomas, A. A.; Shouval, R.; Batlevi, C. L.; Brentjens, R. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A phase II study of ruxolitinib pre-, during- and post-hematopoietic celltransplantation for patients with primary or secondary myelofibrosis
    Meeting Abstract

    Hobbs, G.; Kim, H. T.; Bottoms, A. J. S.; Byrne, M. T.; Schroeder, M. A.; Tamari, R.; Wall, S. A.; Defilipp, Z.; El-Jawahri, A.; McAfee, S.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • The ECHELON-2 Trial: 5-year exploratory subgroup analyses of a randomized, double-blind, phase 3 study of brentuximab vedotin and CHP (A + CHP) vs CHOP in frontline treatment of pts with CD30-positive peripheral T-cell lymphoma
    Meeting Abstract

    Horwitz, S. M.; Savage, K. J.; Illidge, T.; Plyer, S. P.; Advani, R.; Shustov, A. R.; Bartlett, N. L.; Pro, B.; Jacobsen, E. D.; Koch, R.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase 2a study of the dual SYK/JAK inhibitor cerdulatinib (ALXN2075) as monotherapy in patients with relapsed/refractory peripheral T-cell lymphoma
    Meeting Abstract

    Horwitz, S. M.; Feldman, T. A.; Ye, J. C.; Khodadoust, M. S.; Munoz, J.; Hamlin, P. A.; Kim, Y. H.; Wilcox, R. A.; Patel, M. R.; Coffey, G. P.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Updates from ongoing, first-in-human phase 1 dose escalation and expansion study of TTI-621, a novel biologic targeting CD47, in patients with relapsed or refractory hematologic malignancies
    Meeting Abstract

    Horwitz, S. M.; James, M. F.; Maris, M.; Lue, J. K.; Sawas, A.; Okada, C.; Feldman, T. A.; Sokol, L.; Mei, M.; Flinn, I. W.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Nanatinostat (Nstat) and valganciclovir (VGCV) in relapsed/refractory (R/R) Epstein-Barr virus-positive (EBV (+)) lymphomas: Final results from the phase 1b/2 VT3996-201 study
    Meeting Abstract

    Haverkos, B. M.; Alpdogan, O.; Baiocchi, R.; Brammer, J. E.; Feldman, T. A.; Capra, M.; Brem, E. A.; Nair, S. M.; Scheinberg, P.; Pereira, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • T-cell lymphomas: Online education significantly improves clinicians' knowledge of therapeutic advances
    Meeting Abstract

    Heller, E. J.; Williams, S. L.; Smith, K. P.; Horwitz, S. M.
    Blood (2021)

    Fulltext@MSK | Save
  • Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): A long-term follow-up of the randomized, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network
    Meeting Abstract

    Hermine, O.; Jiang, L.; Walewski, J.; Bosly, A.; Szymczyk, M.; Thieblemont, C.; Pott, C.; Salles, G.; Feugier, P.; Hübel, K.; more...
    Blood (2021)

    Fulltext@MSK | Save